{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:05:49Z","timestamp":1793869549322,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.eururo.2016.12.016","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T21:07:47Z","timestamp":1483736867000},"page":"961-969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":178,"title":["Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer"],"prefix":"10.1016","volume":"71","author":[{"given":"Emil","family":"Christensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Birkenkamp-Demtr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iver","family":"Nordentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"H\u00f8yer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstin","family":"van der Keur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"van Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Zwarthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Agerb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Falck","family":"\u00d8rntoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Bjerggaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2016.12.016_bib0155","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2016.12.016_bib0160","doi-asserted-by":"crossref","unstructured":"Babjuk M, B\u00f6hle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447\u201361.","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"10.1016\/j.eururo.2016.12.016_bib0165","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2016.12.016_bib0170","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00345-006-0061-7","article-title":"Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure","volume":"24","author":"Stein","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0175","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0180","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2016.12.016_bib0200","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.12.016_bib0205","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0210","doi-asserted-by":"crossref","first-page":"e13821","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2016.12.016_bib0215","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1158\/1078-0432.CCR-10-2659","article-title":"Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers","volume":"17","author":"Reinert","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2016.12.016_bib0220","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.juro.2011.03.141","article-title":"Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay","volume":"186","author":"Zuiverloon","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","article-title":"Circulating tumor DNA as a liquid biopsy for cancer","volume":"61","author":"Heitzer","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2016.12.016_bib0230","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/clinchem\/46.8.1078","article-title":"Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism","volume":"46","author":"Botezatu","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.eururo.2016.12.016_bib0235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtroder","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0240","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2016.12.016_bib0245","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","article-title":"Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery","volume":"65","author":"Reinert","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.eururo.2016.12.016_bib0250","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.eururo.2011.01.048","article-title":"High expression of karyopherin-alpha2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy","volume":"59","author":"Jensen","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0255","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1038\/onc.2012.381","article-title":"A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response","volume":"32","author":"Schepeler","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2016.12.016_bib0260","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdw037","article-title":"Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer","volume":"27","author":"Jamal-Hanjani","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0265","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/14737159.2016.1254551","article-title":"The potential use of urine cell free DNA as a marker for cancer","volume":"16","author":"Salvi","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.eururo.2016.12.016_bib0270","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1038\/ncomms9760","article-title":"Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer","volume":"6","author":"Murtaza","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2016.12.016_bib0275","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827b","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2016.12.016_bib0280","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1200\/JCO.2003.05.073","article-title":"Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome","volume":"21","author":"van Rhijn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0285","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"41","key":"10.1016\/j.eururo.2016.12.016_bib0305","doi-asserted-by":"crossref","first-page":"67435","DOI":"10.18632\/oncotarget.11883","article-title":"Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up","volume":"7","author":"Critelli","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.eururo.2016.12.016_bib0295","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/path.2507","article-title":"The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour","volume":"218","author":"Kompier","year":"2009","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2016.12.016_bib0300","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.molonc.2016.08.003","article-title":"Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma","volume":"10","author":"Thomsen","year":"2016","journal-title":"Mol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816309204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283816309204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T13:20:51Z","timestamp":1601299251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283816309204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0302283816309204"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2016.12.016","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2016.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}